Halim Hasseri, Chunhacha Preedakorn, Suwanborirux Khanit, Chanvorachote Pithi
Pharmaceutical Technology (International) Program, Organisms and Endophytic Fungi (BNPME), Department of Pharmacognosy and Pharmaceutical Botany, Chulalongkorn University, Pathumwan, Bangkok, Thailand.
Anticancer Res. 2011 Jan;31(1):193-201.
Renieramycin M, has been shown to exhibit promising anticancer activity against some cancer cell lines; however, the underlying mechanism remains unknown.
Renieramycin M was isolated from the blue sponge Xestospongia sp. Anticancer and antimetastatic activities of renieramycin M were investigated in human non-small cell lung cancer cells.
Renieramycin M treatment caused p53 activation, which subsequently down-regulated anti-apoptotic MCL-1 and BCL-2 proteins, while the level of pro-apoptotic BAX protein was not altered. The subtoxic concentrations of renieramycin M significantly decreased invasion and migration abilities of cancer cells. In addition, this compound showed a strong inhibitory effect on anchorage-independent growth of the cells.
These results reveal that renieramycin M induced lung cancer cells apoptosis through p53-dependent pathway and the compound may inhibit progression and metastasis of lung cancer cells.
海兔霉素M已被证明对某些癌细胞系具有有前景的抗癌活性；然而，其潜在机制仍不清楚。
海兔霉素M从蓝色海绵Xestospongia sp.中分离得到。在人非小细胞肺癌细胞中研究了海兔霉素M的抗癌和抗转移活性。
海兔霉素M处理导致p53激活，随后下调抗凋亡的MCL-1和BCL-2蛋白，而促凋亡的BAX蛋白水平未改变。海兔霉素M的亚毒性浓度显著降低癌细胞的侵袭和迁移能力。此外，该化合物对细胞的非贴壁依赖性生长显示出强烈的抑制作用。
这些结果表明海兔霉素M通过p53依赖途径诱导肺癌细胞凋亡，并且该化合物可能抑制肺癌细胞的进展和转移。
